-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
February 23, 2021 //---In a new study, researchers from Pennsylvania State University reported that in a clinical trial initiated by the Perelman School of Medicine at the University of Pennsylvania, a large number of non- Hodgkin's lymphoma (NHL) patients are still in remission five years after receiving chimeric antigen receptor (CAR) T cell (CAR-T) therapy (called Kymriah).
The corresponding author of the paper, Dr.
The co-authors of this study also include Dr.
These researchers also studied the long-term persistence of CAR-T cells and found that 50% of patients experienced and maintained remission after the first year, the CAR19 transgene was not detected after five years, and 18 were infused with CAR-T Among the patients whose lymphoma recurred within one year, only one had lost the CAR19 transgene.
These findings are a follow-up study of the same clinical trial published by Schuster and other researchers in the NEJM journal in 2017, and include patient treatment results collected at 28 months.
Diffuse large B-cell lymphoma accounts for about 30% of all NHL, and it is estimated that there are 27,000 newly diagnosed DLBCL patients in the United States each year.
References:
References:
1.
Elise A.
Chong et al.
Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy .
NEJM, 2021, doi:10.
1056/NEJMc2030164.
2.
CAR T therapy shows long-lasting remissions in non-hodgkin lymphoma
https://medicalxpress.
com/news/2021-02-car-therapy-long-lasting-remissions-non-hodgkin.
html Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy